These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 26646276)

  • 1. Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group.
    Sinn M; Dälken L; Striefler JK; Bischoff S; Schweitzer N; Pelzer U; Dörken B; Riess H; Stieler JM
    Pancreas; 2016 Apr; 45(4):601-5. PubMed ID: 26646276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer.
    Ekström A; Brun E; Eberhard J; Segerlantz M
    Acta Oncol; 2021 Dec; 60(12):1580-1588. PubMed ID: 34486921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):105-11. PubMed ID: 21382702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy.
    Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
    Pancreas; 2014 Apr; 43(3):411-6. PubMed ID: 24622071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Cros J; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Eur J Cancer; 2013 Aug; 49(12):2643-53. PubMed ID: 23726265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer.
    Klein F; Bahra M; Schirmeier A; Al-Abadi H; Pratschke J; Pelzer U; Oettle H; Striefler J; Riess H; Sinn M
    J Surg Oncol; 2015 Jul; 112(1):66-71. PubMed ID: 26193339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer.
    Lee JE; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Bang S
    Gut Liver; 2020 Jan; 14(1):135-143. PubMed ID: 30974927
    [No Abstract]   [Full Text] [Related]  

  • 8. Survival analysis of 272 patients with pancreatic cancer undergoing combined treatment.
    Cao N; Zhao A; Zhao G; Wang X; Han B; Lin R; Zhao Y; Yang J
    Integr Cancer Ther; 2015 Mar; 14(2):133-9. PubMed ID: 25567328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
    Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
    Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C
    J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External validation of 2 prognostic indices for patients with advanced pancreatic cancer treated with first-line therapy.
    Haas M; Laubender RP; Klose C; Schulz C; Mansmann U; Boeck S; Heinemann V
    Pancreas; 2012 Jul; 41(5):738-44. PubMed ID: 22286380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
    Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
    Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
    Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
    Di Maio M; Krzakowski M; Fougeray R; Kowalski DM; Gridelli C
    Lung Cancer; 2012 Jul; 77(1):116-20. PubMed ID: 22361218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
    Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
    Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer.
    Cantore M; Rabbi C; Fiorentini G; Oliani C; Zamagni D; Iacono C; Mambrini A; Del Freo A; Manni A
    Oncology; 2004; 67(2):93-7. PubMed ID: 15539911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma.
    Bachet JB; Gay F; Maréchal R; Galais MP; Adenis A; MsC DS; Cros J; Demetter P; Svrcek M; Bardier-Dupas A; Emile JF; Hammel P; Ebenezer C; Berlier W; Godfrin Y; André T
    Pancreas; 2015 Oct; 44(7):1141-7. PubMed ID: 26355551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.